Articles from Orbis Medicines

Orbis Medicines, a leader in the discovery of next-generation macrocycles, oral medicines with biologics-like potency, today announced the appointment of Joanne Smith-Farrell, Ph.D., as Chief Executive Officer. She succeeds co-founder Morten Graugaard, who becomes Chief Business Officer.

Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases. The agreement enables the acceleration of the development of a new class of orally available medicines for high-value therapeutic targets.

Orbis Medicines, a leader in oral macrocycle drug discovery, and the Danish Center for AI Innovation (DCAI) today announced that Orbis has begun using Denmark’s first AI supercomputer, Gefion, which is owned and operated by DCAI. Gefion will allow the company to accelerate its mission of developing oral alternatives to widely used biologics and targeting important intra- and extracellular proteins that are currently difficult or impossible to drug with orally bioavailable compounds.

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific Officer, President, Pfizer Research & Development, as Chairperson of the Board of Directors.

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the close of a EUR 90 million Series A funding round, bringing the total amount raised by the company to EUR 116 million. The funds will support the development of Orbis’ pipeline of next-generation oral macrocycle drugs, called ‘nCycles.’ This financing was led by NEA (New Enterprise Associates) with participation from new investors including Eli Lilly and Company, Cormorant, the Export and Investment Fund of Denmark and founding investors Novo Holdings and Forbion. Morten Graugaard has been named the Chief Executive Officer of Orbis Medicines following nearly three years serving as Executive Chair of its Board of Directors. Mr. Graugaard brings more than 20 years of experience in life sciences including venture investing, R&D, business development, corporate development and strategy to Orbis’ leadership team.

Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a research collaboration and option to an exclusive license with Vivtex, a biotech company aiming to transform the development of oral biologic therapies for major diseases. The collaboration will enable Orbis to utilize Vivtex’s GI-ORIS™ platform for gut permeability screening to evaluate the oral bioavailability of Orbis’ portfolio of next-generation macrocycle drugs it calls ‘nCycles’.

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces its launch with a €26 million financing led by global life sciences investor Novo Holdings and European life sciences venture firm Forbion. The funding will support Orbis’ expansion and advancement of its portfolio of next-generation macrocycle drugs it calls ‘nCycles’. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties, defined by the presence of a cyclic structure. nCycles are systematically designed by Orbis’ nGen1 platform to be orally bioavailable and membrane permeable, solving decades-long challenges in macrocycle drug design.